Recent News

• 11.02.2026 - Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
• 09.04.2026 - Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
• 09.03.2026 - Rein Therapeutics to Present at Upcoming September Investor Conferences
• 08.20.2026 - Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
• 08.14.2026 - Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• 08.04.2026 - Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
• 07.21.2026 - Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
• 06.11.2026 - Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
• 05.18.2026 - Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
• 05.01.2026 - Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Recent Filings

• 09.04.2026 - 8-K Current report
• 09.04.2026 - EX-99.1 EX-99.1
• 08.27.2026 - 8-K Current report
• 08.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.21.2026 - 8-K Current report
• 07.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.08.2026 - ARS Annual Report to Security Holders